Hassard James 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jun 24, 2024
Insider Transaction Report
Form 4
Hassard James
Chief Commercial Officer
Transactions
- Sale
Common Stock
2024-06-21$44.66/sh−15,000$669,900→ 29,259 total - Exercise/Conversion
Stock option (Right to Buy)
2024-06-21−15,000→ 145,000 totalExercise: $19.73Exp: 2032-03-10→ Common Stock (15,000 underlying) - Exercise/Conversion
Common Stock
2024-06-21$19.73/sh+15,000$295,950→ 44,259 total
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.66 per share. The range of sales prices on the transaction date was $43.96 to $45.11 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- [F3]The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.